EDESA BIOTECH, INC. Deferred Offering Costs
EDESA BIOTECH, INC. (EDSA) had Deferred Offering Costs of $116.61 thousand as of 2019-12-31, per its 10-Q filed 2020-02-13.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2020-02-13
- 2019-12-31: Deferred Offering Costs $116.61K.
- 2019-09-30: Deferred Offering Costs $0.00.
- 2016-06-30: Deferred Offering Costs $238.44K.
- 2015-09-30: Deferred Offering Costs $0.00.
| Period end | Deferred Offering Costs |
|---|---|
| 2019-12-31 | $116.61K 10-Q · filed 2020-02-13 |
| 2019-09-30 | $0.00 10-Q · filed 2020-02-13 |
| 2016-06-30 | $238.44K 10-Q · filed 2016-08-09 |
| 2015-09-30 | $0.00 10-Q · filed 2016-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |